Skip to content
DraconiticResearch
Search Sources API
197,761 studies31 sourcesUpdated 31 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles for Immunomodulation in Osteoarthritis

  • Michelle B. R. G. Ley1,2
  • Marc C. Philippon1,2
  • Ramy S. Labib1,2
  • Miguel Fuentes-Chandia3,4,5
  • Chao Liu6
  • Thomas M. Best1,2
  • Rodrigo A. Somoza3
  • Dimitrios Kouroupis1,2
6 affiliations
  1. 1Department of Orthopedics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
  2. 2Diabetes Research Institute & Cell Transplant Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
  3. 3Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA
  4. 4Center for the Multimodal Evaluation of Structural Tissues, Case Western Reserve University, Cleveland, OH 44106, USA
  5. 5Asclepii Inc., Cleveland, OH 44106, USA
  6. 6Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
Open at sourceDOICite

Abstract

Osteoarthritis (OA) is a heterogeneous disorder affecting multiple joint tissues, in which structural degeneration may be accompanied by varying degrees of synovial inflammation and immune–stromal dysregulation. Mesenchymal stem/stromal cells (MSCs) have demonstrated immunomodulatory and tissue-protective properties, increasingly linked to paracrine signaling. Comparative studies suggest that extracellular vesicles (EVs) make an important, but not exclusive, contribution to MSC paracrine activity, with soluble secretome components providing potentially complementary effects. Drawing on literature identified primarily through PubMed and Scopus and clinical trial records from ClinicalTrials.gov (updated through September 2026), this narrative review examines the immunomodulatory role of MSC-derived EVs (MSC-EVs) in OA, with emphasis on their interactions with the joint immune microenvironment and their contribution to tissue protection. Across experimental OA models, MSC-EVs have been reported to reduce synovitis, cartilage degeneration, subchondral bone alterations, and pain-related outcomes, although responses vary with MSC source, EV composition, engineering strategies, disease context, and treatment regimen. Mechanistically, the most consistent evidence supports modulation of macrophage-associated inflammatory responses, whereas effects on adaptive immune populations remain less established and are largely derived from non-OA models. Clinical evidence remains limited and currently provides mainly preliminary information on feasibility and short-term tolerability, with insufficient evidence to establish therapeutic efficacy. Overall, MSC-EVs represent a potential cell-free immunomodulatory approach for OA, but standardized manufacturing, product characterization, dosing, and rigorously controlled clinical trials are required to define their therapeutic value.

Related

  1. Mesenchymal stem cell-derived extracellular vesicles in diabetes: immunomodulation and therapeutic prospects
    Lingli Ma, Ning Hou, Xuejiao Zhang +6
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMCPMCEurope PMC
  2. Pulsed Focused Ultrasound–Mediated Mechanopriming Enhances the Therapeutic Efficacy of Mesenchymal Stromal Cell–Derived Extracellular Vesicles in Acute Respiratory Distress Syndrome
    Shashank Chetty, Shobha Regmi, Abantika Ganguly +5
    Journal of extracellular vesiclesPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMCDOAJ
  3. Mechanical Loading Reshapes Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicle microRNA Cargo Toward Predicted Immunomodulatory and EV Cargo-Trafficking Pathways: An In Vitro Mechanobiology Study
    Mahammad Gardashli, Elena Della Bella, Manuel Herzog +3
    BiomoleculesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  4. Adipose-derived stem cell-derived extracellular vesicles promote critical-sized bone defect repair by enhancing the homing of bone marrow mesenchymal stem cells
    Jingjie Yang, Jing Jing, Xuesha Tong +4
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationCrossref
  5. Epithelial-endothelial barrier dysfunction and oxidative stress in ARDS subphenotypes: comparative efficacy of extracellular vesicles derived from bone marrow (MSC-EVs) and adipose tissue (ASC-EVs) mesenchymal stem cells
    A. Burello, G. Tiberi, P. A. D. Villegas +14
    medRxivPreprintAll rights reservedFull textMolecular biology & gene regulationmedRxiv

Cite

BibTeXRIS
BibTeX
@article{ley2026mesenchymal,
  title = {{Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles for Immunomodulation in Osteoarthritis}},
  author = {Michelle B. R. G. Ley and Marc C. Philippon and Ramy S. Labib and Miguel Fuentes-Chandia and Chao Liu and Thomas M. Best and Rodrigo A. Somoza and Dimitrios Kouroupis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = nov,
  doi = {10.3390/ijms27219922},
  url = {https://www.mdpi.com/1422-0067/27/21/9922},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles for Immunomodulation in Osteoarthritis
AU  - Michelle B. R. G. Ley
AU  - Marc C. Philippon
AU  - Ramy S. Labib
AU  - Miguel Fuentes-Chandia
AU  - Chao Liu
AU  - Thomas M. Best
AU  - Rodrigo A. Somoza
AU  - Dimitrios Kouroupis
PY  - 2026
DA  - 2026/11/05
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms27219922
UR  - https://www.mdpi.com/1422-0067/27/21/9922
AB  - Osteoarthritis (OA) is a heterogeneous disorder affecting multiple joint tissues, in which structural degeneration may be accompanied by varying degrees of synovial inflammation and immune–stromal dysregulation. Mesenchymal stem/stromal cells (MSCs) have demonstrated immunomodulatory and tissue-protective properties, increasingly linked to paracrine signaling. Comparative studies suggest that extracellular vesicles (EVs) make an important, but not exclusive, contribution to MSC paracrine activity, with soluble secretome components providing potentially complementary effects. Drawing on literature identified primarily through PubMed and Scopus and clinical trial records from ClinicalTrials.gov (updated through September 2026), this narrative review examines the immunomodulatory role of MSC-derived EVs (MSC-EVs) in OA, with emphasis on their interactions with the joint immune microenvironment and their contribution to tissue protection. Across experimental OA models, MSC-EVs have been reported to reduce synovitis, cartilage degeneration, subchondral bone alterations, and pain-related outcomes, although responses vary with MSC source, EV composition, engineering strategies, disease context, and treatment regimen. Mechanistically, the most consistent evidence supports modulation of macrophage-associated inflammatory responses, whereas effects on adaptive immune populations remain less established and are largely derived from non-OA models. Clinical evidence remains limited and currently provides mainly preliminary information on feasibility and short-term tolerability, with insufficient evidence to establish therapeutic efficacy. Overall, MSC-EVs represent a potential cell-free immunomodulatory approach for OA, but standardized manufacturing, product characterization, dosing, and rigorously controlled clinical trials are required to define their therapeutic value.
SN  - 1422-0067
ER  -